Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 62Letrozole 56Fulvestrant 55Trastuzumab 50palbociclib 42pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25abemaciclib 24Tamoxifen 24Capecitabine 24ribociclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × enfortumab vedotin × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡